In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 372-380

  Gnoth, Mark Jean ^a   Buetehorn, Ulf ^a   Muenster, Uwe ^a   Schwarz, Thomas ^a   Sandmann, Steffen ^a  

^a Building 468   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CIMETIDINE; CLARITHROMYCIN; ERYTHROMYCIN; FLUINDOSTATIN; GLYCOPROTEIN P; IVERMECTIN; KETOCONAZOLE; KETOPROFEN; METHOTREXATE; PHENAZONE; PROPRANOLOL; QUINIDINE; RITONAVIR; RIVAROXABAN; SALAZOSULFAPYRIDINE; VINBLASTINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; CACO-2 CELLS; HUMANS; LLC-PK1 CELLS; MALE; MICE; MICE, KNOCKOUT; MORPHOLINES; P-GLYCOPROTEIN; PROTEIN TRANSPORT; SWINE; THIOPHENES;

EID: 79959522836     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.180240     Document Type: Article

References (35)

1. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, and Kim RB (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660. (Pubitemid 30390404)
2. Cook CS, Berry LM, and Burton E (2004) Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. Xenobiotica 34:215-228. (Pubitemid 38478891)
3. Fromm MF, Kim RB, Stein CM, Wilkinson GR, and Roden DM (1999) Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99:552-557. (Pubitemid 29061872)
4. Grès MC, Julian B, Bourrié M, Meunier V, Roques C, Berger M, Boulenc X, Berger Y, and Fabre G (1998) Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharm Res 15:726-733. (Pubitemid 28275649)
5. Gupta A, Zhang Y, Unadkat JD, and Mao Q (2004) HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 310:334-341. (Pubitemid 38812728)
6. Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, Ruan P, Wu H, Lee J, Flexner C, et al. (2003) Steady-state pharmacokinetic interaction of modified- dose indinavir and rifabutin. Clin Pharmacol Ther 73:159-169. (Pubitemid 36269667)
7. Hidalgo IJ, Raub TJ, and Borchardt RT (1989) Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749. (Pubitemid 19057595)
8. Huls M, Brown CD, Windass AS, Sayer R, van den Heuvel JJ, Heemskerk S, Russel FG, and Masereeuw R (2008) The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 73:220-225.
9. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, et al. (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
10. Kawahara M, Sakata A, Miyashita T, Tamai I, and Tsuji A (1999) Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J Pharm Sci 88:1281-1287.
11. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, Lufft V, Wand DD, Philipp T, and Bruck H (2010) Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 70:703-712.
12. Kubitza D, Becka M, Voith B, Zuehlsdorf M, and Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78:412-421. (Pubitemid 41393676)
13. Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, et al. (2003) Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther 304:1161-1171. (Pubitemid 36254429)
14. Lang D, Freudenberger C, and Weinz C (2009) In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab Dispos 37:1046-1055.
15. Leusch A, Volz A, Müller G, Wagner A, Sauer A, Greischel A, and Roth W (2002) Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice. Eur J Pharm Sci 16:119-128. (Pubitemid 34790254)
16. Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DK, van Asperen J, Borst P, and Schinkel AH (1996) Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol 119:1038-1044. (Pubitemid 26366502)
17. McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, and Rainey PM (2007) Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 91:269-278.
18. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, and Eriksson BI (2008) Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100:453-461.
19. Mueck W, Eriksson B, Borris L, Dahl O, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muehlhofer E, and Misselwitz F (2006) Rivaroxaban for thromboprophylaxis in patients undergoing total hip replacement: comparison of pharmacokinetics and pharmacodynamics with once- and twice-daily dosing. Blood (ASH Annu Meeting Abstracts) 108:903.
20. Muenster U, Grieshop B, Ickenroth K, and Gnoth MJ (2008) Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm Res 25:2320-2326.
21. Nakayama A, Saitoh H, Oda M, Takada M, and Aungst BJ (2000) Region-dependent disappearance of vinblastine in rat small intestine and characterization of its P-glycoprotein-mediated efflux system. Eur J Pharm Sci 11:317-324.
22. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, and Straub A (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost 3:514-521. (Pubitemid 41632877)
23. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628. (Pubitemid 32979675)
24. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, and Polli JW (2006) In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786-792.
25. Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, Reinemer P, and Perzborn E (2005) Discovery of the novel antithrombotic agent 5-chloro-N-([(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl] methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 48:5900-5908. (Pubitemid 41324601)
26. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, et al. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) Pglycoproteins. Proc Natl Acad Sci USA 94:4028-4033. (Pubitemid 27180493)
27. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, and te Riele HP (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the bloodbrain barrier and to increased sensitivity to drugs. Cell 77:491-502.
28. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, and Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
29. Schwab D, Fischer H, Tabatabaei A, Poli S, and Huwyler J (2003) Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem 46:1716-1725.
30. Toyobuku H, Tamai I, Ueno K, and Tsuji A (2003) Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug. J Pharm Sci 92:2249-2259. (Pubitemid 37356698)
31. Troutman MD and Thakker DR (2003) Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res 20:1210-1224. (Pubitemid 36951846)
32. van de Vrie W, Marquet RL, Stoter G, De Bruijn EA, and Eggermont AM (1998) In vivo model systems in P-glycoprotein-mediated multidrug resistance. Crit Rev Clin Lab Sci 35:1-57. (Pubitemid 28154244)
33. van Montfoort JE, Schmid TE, Adler ID, Meier PJ, and Hagenbuch B (2002) Functional characterization of the mouse organic-anion-transporting polypeptide 2. Biochim Biophys Acta 1564:183-188. (Pubitemid 34717884)
34. Weinz C, Schwarz T, Kubitza D, Mueck W, and Lang D (2009) Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 37:1056-1064.
35. Zhang L, Strong JM, Qiu W, Lesko LJ, and Huang SM (2006) Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm 3:62-69. (Pubitemid 43331752)